logo
Plus   Neg
Share
Email

Eli Lilly Announces FDA Approval Of CYRAMZA For New Indication - Quick Facts

Eli Lilly and Company (LLY) announced the FDA has approved CYRAMZA for the treatment of patients with hepatocellular carcinoma who have a high alpha-fetoprotein and have been treated with sorafenib. As a result of the approval of the new indication, FDA has removed the boxed warning from the labeling of CYRAMZA. With the latest approval, the company has now received five FDA approvals for CYRAMZA.

Eli Lilly noted that it has filed applications for marketing authorization in the European Union and Japan for CYRAMZA and regulatory action is expected in mid-2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration or FDA announced on its website that pharma major Pfizer, Inc. issued recall of two lots of tablets meant to treat acute migraine in adults for concerns over bacteria infection. The pharma company is recalling two lots of Relpax (eletriptan hydrobromide) 40 mg tablets for potential presence of Genus Pseudomonas and Burkholderia bacteria. Cosmetics company Revlon Inc. (REV) is reportedly considering a potential sale of parts or all of its business. According to Bloomberg, Revlon has retained financial advisers from Goldman Sachs Group Inc. to explore strategic alternatives. No deal has been reached yet, but Revlon is exploring all... China's Lenovo Group Ltd. warned it may have to raise prices of its products if the U.S. moves ahead with the decision to impose additional tariffs on Chinese goods, according to a report by Reuters. The warning by Lenovo, the world's largest PC maker, comes amid the escalating trade war between the U.S. and China that has raised concerns about the global economic outlook.
Follow RTT